Author’s response to reviews

Title: Phosphatidylinositol 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro

Authors:

Dmitriy Smolensky (dsmolens@vols.utk.edu)

Kusum Rathore (krathore@utk.edu)

Maria Cekanova (mcekanov@utk.edu)

Version: 2 Date: 05 Nov 2015

Author’s response to reviews:

November 5th, 2015

TO: Dr. Dafne Solera
BMC Cancer
236 Gray's Inn Road
London WC1X 8HB, United Kingdom
E-mail: BMC Cancer: bmccancer@biomedcentral.com

FROM: Dr. Maria Cekanova

Research Associate Professor
Phone: 865-389-5222

E-mail: mcekanov@utk.edu


Dear Dr. Dafne Solera,

Thank you very much for your consideration to accept our article for publication after addressing the reviewer’s minor comments and concerns.

Please kindly find our revised version of manuscript with attached responses to reviewer’s comments on our manuscript entitled: “Phosphatidylinositol 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro.”
Our responses are labeled in italic bold in file with reviewers' comments containing a point-by-point explanation with cross-references to the corresponding change in the manuscript.

Thank you and please let me know if you have additional questions or comments.

Sincerely,

Maria Cekanova, RNDr, PhD
Research Associate Professor

Minor editorial concerns:

1) Please include the title “Competing interests” before your competing interest statement

MC: We included title and statement to our manuscript

2) Please change the title “Source of funding” to “Acknowledgments”

MC: We changed the title accordingly.